Skip to main content
. 2018 Mar 13;7(7):e1442167. doi: 10.1080/2162402X.2018.1442167

Figure 1.

Figure 1.

Distribution of MDSCs in peripheral blood and tumor samples from patients with ESCC. (A) Single cell suspensions were prepared from peripheral blood and tumor tissues from patients with ESCC (n = 75) or healthy donors (n = 15), and analyzed using flow cytometry. (B, C) Inhibition of T cell proliferation and function were assessed using flow cytometry. (D) Clinical samples were divided into two groups according to accumulation of PMN-MDSCs in tumor tissue, and overall survival was analyzed (n = 54). (E) Survival of patients correlated with CD33 expression from TCGA database (n = 93), as a PMN-MDSC marker. *P < 0.05; **P < 0.01.